<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/233062-4-3-chloro-4-fluorophenyl-amino-6-4-n-n-dimethylamino-1-oxo-2-buten-1-yl-amino-7-s-tetrahydrofuran-3-yloxy-quinazoline by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:30:05 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 233062:&quot;4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)-1-OXO-2-BUTEN-1-YL]AMINO}-7-((S)-TETRAHYDROFURAN-3-YLOXY)-QUINAZOLINE&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-{[4-(N,N-DIMETHYLAMINO)-1-OXO-2-BUTEN-1-YL]AMINO}-7-((S)-TETRAHYDROFURAN-3-YLOXY)-QUINAZOLINE&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-l-oxo-2-buten-l-yl]amino}-7-((S)- tetrahydrofuran-3-yloxy) -quinazoline of formula (VII) comprising the following synthesis steps (a)Reacting N4 - (3-chloro-4-fIuoro-phenyl)- 7- (tetrahydrofuran - 3 - yloxy) quinazoline-4,6-diamine of formula (V) in suitable solvents after corresponding activation with di-(C1-4-alkyl)-phosphonoacetic acid and (b) reacting the resulting di-(C1-4-alkyl)-{[4- (3 -chloro - 4- fluoro-phenylamino) -7- ((S) - tetrahydrofuran - 3-yloxy)-quinazolin-6-ylcarbamoyl]-methyl}-phosphonate of formula (VI), wherein R1 denotes C1-4-alkyl group, with the aldehyde of formula or a corresponding aldehyde equivalent such as a hydrate or acetal, using suitable organic or inorganic bases to get the compound of formula VII.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The invention relates to an improved process for preparing aminocrotonyl<br>
compounds such as for example 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-<br>
1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline<br>
and the physiologically acceptable salts thereof, particularly 4-[(3-chloro-4-<br>
fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-<br>
tetrahydrofuran-3-yloxy)-quinazoline dimaleate, as well as 4-[(3-chloro-4-<br>
fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((^-<br>
tetrahydrofuran-3-yloxy)-quinazoline dimaleate and the use thereof for preparing<br>
pharmaceutical compositions.<br>
4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]-<br>
amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline has the following structure:<br>
and is already known from WO 02/50043, which describes compounds with valuable<br>
pharmacological properties, including in particular an inhibiting effect on signal<br>
transduction mediated by tyrosinekinases and an inhibitory effect on signal<br>
transduction mediated by the Epidermal Growth Factor receptor (EGF-R). Therefore,<br>
compounds of this type are suitable for the treatment of diseases, particularly for the<br>
treatment of tumoral diseases, diseases of the lungs and respiratory tract and<br>
diseases of the gastrointestinal tract and bile duct and gall bladder.<br>
WO 02/50043 discloses a method of preparation wherein aminocrotonyl compounds<br>
(IV) such as for example 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,Ndimethylamino)-<br>
1-oxo-2-buten-1-yl]amino}-7-((^-tetrahydrofuran-3-yloxy)-<br>
quinazoline are prepared in a one-pot reaction from the corresponding aniline<br>
component (II), bromocrotonic acid (III), oxalyl chloride and a secondary amine <br>
In this process the yield was at most 50 %. In addition, purification was generally<br>
carried out by column chromatography. Therefore, the method of preparing 4-[(3-<br>
chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-<br>
((S)-tetrahydrofuran-3-yloxy)-quinazoline was not suitable on an industrial scale.<br>
Furthermore, the method had the disadvantage that bromocrotonic acid is not<br>
commercially available in large amounts and also the corresponding methyl<br>
bromocrotonate is only available in a purity of approx. 80 %. These circumstances<br>
also militate against the suitability of this process for the industrial production of 4-[(3-<br>
chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-<br>
((S)-tetrahydrofuran-3-yloxy)-quinazoline.In the light of the above disadvantages of the known method of production, the aim of<br>
the present invention is to provide a process which allows the production of<br>
aminocrotonylarylamides, particularly 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,Ndimethylamino)-<br>
1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-<br>
quinazoline, using highly pure starting materials which are readily available and<br>
without any great technical expenditure. This new process should therefore also be<br>
suitable for synthesis on an industrial scale and hence for commercial application.<br>
This aim is achieved by the process according to the invention for preparing 4-[(3-<br>
chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-<br>
((S)-tetrahydrofuran-3-yloxy)-quinazoline and other aminocrotonyl compounds. In<br>
addition to being industrially practicable with high yields the method of synthesis<br>
according to the invention also has the advantages of very good chemical purities<br>
and a low cis content of less than 0.1%.<br>
In the process according to the invention the corresponding aminoaryl compound (V)<br>
is reacted with a di-(Ci-4-alkyl)-phosphonoacetic acid, preferably with diethylphosphonoacetic<br>
acid, in suitable solvents, after corresponding activation, preferably with<br>
1,1-carbonyldiimidazole, 1,1-carbonylditriazole or propanephosphonic anhydride,<br>
particularly preferably with 1,1-carbonyldiimidazole, according to Diagram 2. The<br>
solvent used may be for example tetrahydrofuran (THF), dimethylformamide (DMF)<br>
or ethyl acetate.<br>
The activation may be carried out by any possible method of amide linking, i.e. for<br>
example with 1,1-carbonyldiimidazole, 1,1-carbonylditriazole, DCC (N,Ndicyclohexylcarbodiimide),<br>
EDC (N'-(dimethylaminopropyl)-N-ethylcarbodiimide),<br>
TBTU (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate),<br>
thiazolidine-2-thione or by conversion into the corresponding acid chloride, possibly<br>
using thionyl chloride. If desired the activation may be carried out using organic<br>
bases such as triethylamine or pyridine, while DMAP (dimethylaminopyridine) may<br>
additionally be added. Suitable solvents include DMF, THF, ethyl acetate, toluene,<br>
chlorinated hydrocarbons or mixtures thereof.<br>
In the formulae that follow<br>
X denotes a methyne group or a nitrogen atom,<br>
Ra denotes a benzyl, 1 -phenylethyl or 3-chloro-4-fluorophenyl group and<br>
R1 denotes a straight-chain or branched Ci-4-alkyl group.<br>
The process is preferably used for compounds wherein<br>
X denotes a nitrogen atom,<br>
Ra denotes a 3-chloro-4-fluorophenyl group and<br>
R1 denotes an ethyl group.<br>
a) di-(Ci-4-alkyl)-phosphonoacetic acid, activating agent<br>
The arylamide (VI) thus obtained in a high yield and high purity is reacted with the<br>
corresponding 2-aminoacetaldehyde using suitable organic or inorganic bases in the<br>
sense of a Wittig-Horner-Emmons reaction (Diagram 3). This reaction may be carried<br>
out directly or after isolation of the compound (VI), for example by precipitation by the<br>
addition of tert-butylmethyl ether, for example. Suitable bases include for example<br>
DBU (1,5-diazabicyclo[4.3.0]non-5-ene), sodium hydroxide and potassium hydroxide,<br>
of which sodium hydroxide and potassium hydroxide are preferred and potassium<br>
hydroxide is particularly preferred. Instead of the aldehyde a corresponding<br>
equivalent, e.g. a hydrate or acetal, may be used, from which the aldehyde is<br>
released (beforehand or in situ).<br>
b) aldehyde, base, THF/water<br>
The acetals used may be for example compounds of the following general type:<br>
wherein R2 to R5 in each case represent a straight-chain or branched CrC4-alkyl<br>
group, while the groups may be identical or different.<br>
Preferably<br>
R3 and R4 in each case represent a methyl group and<br>
R2 and R5 in each case represent an ethyl group.<br>
The aminocrotonylarylamide of formula (VII) thus obtained, for example 4-[(3-chloro-<br>
4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-<br>
tetrahydrofuran-3-yloxy)-quinazoline of formula (I), may then be converted into the<br>
salts thereof, particularly the physiologically acceptable salts thereof, by methods<br>
known perse. Preferably they are converted into fumarates, tartrates or maleates.<br>
The dimaleate of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-<br>
oxo-2-buten-1 -yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline of structural<br>
formula (la) and the conversion of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,Ndimethylamino)-<br>
1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-<br>
quinazoline into its dimaleate as shown in Diagram 4 are particularly preferred. To do<br>
this the compound (I) is dissolved in a suitable solvent, such as for example<br>
methanol, isopropanol, n-butanol or ethanol, optionally with the addition of water,<br>
preferably ethanol, and combined with crystalline maleic acid or a maleic acid<br>
solution, with heating. When ethanol is used as solvent the work is preferably done at<br>
a temperature of between 60 and 75 °C using an ethanolic maleic acid solution. The<br>
reaction conditions are preferably selected so that the desired salt crystallises out as<br>
quickly as possible. Preferably approx. 2 equivalents of maleic acid are used. After<br>
crystallisation has set in the mixture is cooled to ambient temperature, stirred and the<br>
crystals consisting of compound (la) are separated off.<br>
c) maleic acid, ethanol<br>
The starting compound of formula (V) may for example be prepared as follows in<br>
accordance with methods known from the literature.<br>
The quinoline components of formula (V), wherein X = CH, may be obtained starting<br>
from commercially obtainable 3-fluoro-6-nitrophenol (XIV) by alkylation, exchanging<br>
the fluorine atom for an amino group and reacting with ethoxyacrylic acid esters,<br>
ethoxymethylene-cyanoacetic acid esters or ethoxymethylene-malonic acid esters<br>
(Diagram 5a).<br>
The compound thus obtained (XVII) is then converted into the compound (XVIII) as<br>
described in Diagram 6 for the quinazoline analogue<br>
Diagram 5a:<br>
To prepare the compound (V) wherein X = N the following procedure is used:<br>
Starting from commercially obtainable 4-chloro-anthranilic acid (VIII; X = Cl) the<br>
quinazolinone (IX) is obtained by reaction with formamidine-acetate, and is then<br>
nitrogenated using sulphuric acid and concentrated nitric acid (Diagram 5b).<br>
Alternatively, 4-fluoro-anthranilic acid may also be used as the starting material.<br>
d) formamidine-acetate<br>
e) H2SO4, HN03 cone.<br>
The desired regioisomer (X) of the nitrogenation products thus obtained is then<br>
chlorinated, and the chlorination product (XI) is reacted in situ with the corresponding<br>
amine (Diagram 6).<br>
The compound of formula (XII) thus obtained is reacted with (S)-(+)-3-<br>
hydroxytetrahydrofuran to form compound (XIII). Hydrogenation of compound (XIII)or compound (XVIII) from Diagram 5a then yields the starting compound (V) <br>
(XIII): X = N<br>
(XVIII): X = CH<br>
h) (S)-(+)-3-hydroxy-tetrahydrofuran<br>
The invention also relates to 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,Ndimethylamino)-<br>
1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-<br>
quinazoline dimaleate. This salt is particularly suitable for pharmaceutical use as it<br>
exists in only one crystalline modification, which is moreover anhydrous and very<br>
stable.<br>
For pharmaceutical use an active substance not only has to exhibit the desired<br>
activity, but must also conform to additional requirements in order to be allowed to be<br>
used as a pharmaceutical composition. These parameters are to a large extent<br>
connected with the physicochemical nature of the active substance.<br>
Without being restrictive, examples of these parameters are the stability of effect of<br>
the starting material under various environmental conditions, stability during<br>
production of the pharmaceutical formulation and stability in the final medicament<br>
compositions. The pharmaceutically active substance used for preparing the<br>
pharmaceutical compositions should therefore have a high stability which must be<br>
guaranteed even under various environmental conditions. This is absolutely essential<br>
to prevent the use of pharmaceutical compositions which contain, in addition to the<br>
actual active substance, breakdown products thereof, for example. In such cases the<br>
content of active substance in pharmaceutical formulations might be less than that<br>
specified.<br>
The absorption of moisture reduces the content of pharmaceutically active substance<br>
on account of the weight gain caused by the uptake of water. Pharmaceutical<br>
compositions with a tendency to absorb moisture have to be protected from damp<br>
during storage, e.g. by the addition of suitable drying agents or by storing the<br>
medicament in a damp-proof environment. In addition, the uptake of moisture can<br>
reduce the content of pharmaceutically active substance during manufacture if the<br>
medicament is exposed to the environment without being protected from damp in any<br>
way. Preferably a pharmaceutically active substance should therefore have only<br>
limited hygroscopicity.<br>
As the crystal modification of an active substance is important to the reproducible<br>
active substance content of a preparation, there is a need to clarify as far as possible<br>
any existing polymorphism of an active substance present in crystalline form. If there are different polymorphic modifications of an active substance care must be taken to<br>
ensure that the crystalline modification of the substance does not change in the<br>
pharmaceutical preparation later produced from it. Otherwise, this could have a<br>
harmful effect on the reproducible potency of the drug. Against this background,<br>
active substances characterised by only slight polymorphism are preferred.<br>
Another criterion which may be of exceptional importance under certain<br>
circumstances depending on the choice of formulation or the choice of manufacturing<br>
process is the solubility of the active substance. If for example pharmaceutical<br>
solutions are prepared (e.g. for infusions) it is essential that the active substance<br>
should be sufficiently soluble in physiologically acceptable solvents. It is also very<br>
important for drugs which are to be taken orally that the active substance should be<br>
sufficiently soluble.<br>
The problem of the present invention is to provide a pharmaceutically active<br>
substance which not only is characterised by high pharmacological potency but also<br>
satisfies the above-mentioned physicochemical requirements as far as possible.<br>
This problem is solved by 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-<br>
1-oxo-2-buten-1-yl]amino}-7-((-tetrahydrofuran-3-yloxy)-quinazoline<br>
dimaleate.<br>
4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]-<br>
amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate has a melting point of<br>
178°C (cf. the thermoanalysis shown in Figure 2). The crystalline 4-[(3-chloro-4-<br>
fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-<br>
tetrahydrofuran-3-yloxy)-quinazoline dimaleate was investigated further by X-ray<br>
powder diffraction. The diagram obtained is shown in Figure 1.<br>
The following Table lists the data obtained in this analysis:<br>
Table: X-ray powder reflections and intensities (standardised) of the 4-[(3-chloro-<br>
fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-<br>
7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate<br>
(Table Removed) In the preceding Table the value "2 6 [°]" denotes the angle of diffraction in degrees<br>
and the value "dhki [A]" denotes the specified distances in A between the lattice<br>
planes.<br>
The x-ray powder diagrams were recorded, within the scope of the present invention,<br>
using a Bruker D8 Advanced diffractometer fitted with a PSD detector and a Cu<br>
anode as the x-ray source (CuKai radiation, X = 1.5418 A, 40 kV, 40 mA).<br>
The following Examples are intended to illustrate the invention:<br>
Examples:<br>
Example 1<br>
Diethyl{[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahy<br>
auinazolin-6-vlcarbamovl1-methvl)-phosphonate<br>
OEt<br>
3.58 kg of 1,1-carbonyldiimidazole (22.16 mol) are placed in 12.8 litres of<br>
tetrahydrofuran and at 40 °C combined with 4.52 kg (22.16 mol) of<br>
diethylphosphonoacetic acid dissolved in 6.5 litres of tetrahydrofuran. The mixture is<br>
stirred for 30 minutes at 40 °C. The resulting solution is referred to as solution A.<br>
6.39 kg (17.05 mol) of N4-(3-chloro-4-fluoro-phenyl)-7-(tetrahydrofuran-3-<br>
yloxy)quinazoline-4,6-diamine are placed in 26.5 litres of tetrahydrofuran and at 40°C<br>
combined with solution A and stirred for 2 hours at 30°C. 64 litres of tert.-<br>
butylmethylether are added to the suspension and after cooling to 20 °C the<br>
precipitate is removed by centrifuging. It is washed with a mixture of 16 litres of<br>
tetrahydrofuran and 16 litres of tert.-butylmethylether and then with 32 litres of water<br>
and dried at 50 °C.<br>
Yield: 6.58 kg (69.8%) of white crystals, content: HPLC 99.1 Fl%<br>
Example 2<br>
(E)-4-dimethylamino-but-2-enoicacid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-<br>
tetrahvdrofuran-3-vloxv)-auinazolin-6vltamide<br>
5.6 litres of 30 % hydrochloric acid (53.17 mol) are added to 4.4 litres of water. Then<br>
4.28 kg of 95 % (dimethylamino)-acetaldehyde-diethylacetal (26.59 mol) are added<br>
dropwise within 20 minutes at 30°C. The reaction solution is stirred for 8 hours at<br>
35°C stirred, cooled to 5 °C and stored under argon. This solution is referred to as<br>
solution B.<br>
4.55 kg (68.06 mol) of potassium hydroxide are dissolved in 23.5 litres of water and<br>
cooled to -5°C. This solution is referred to as solution C.<br>
5.88 kg (10.63 mol) of diethyl ((4-(3-chloro-4-fluoro-phenylamino)-7-(tetrahydrofuran-<br>
3-yloxy)-quinazoline-6-ylcarbamoyl)-methyl)-phosphonate and 0.45 kg of lithium<br>
chloride (10.63 mol) are placed in 23.5 litres of tetrahydrofuran and cooled to -7 °C.<br>
The cold solution C is added within 10 minutes. Then solution B is added at -7°C<br>
within 1 hour. After stirring for a further hour at -5 °C the reaction mixture is heated<br>
to 20°C and combined with 15 litres of water. After cooling to 3°C the suspension is<br>
suction filtered, the precipitate is washed with water and dried. Yield: 5.21 kg of crude<br>
product, 100 %, water content: 6.7 %<br>
The crystallisation of the crude product is carried out with butyl acetate /<br>
methylcyclohexane<br>
Yield: 78 % purity HPLC 99.4 Fl%, water content 5.4 %<br>
Example 3<br>
(E)-4-dimethylamino-but-2-enoicacid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahvdrofuran-<br>
3-vloxv)-guinazolin-6vl)-amidedimaleate<br>
6.0 kg (12.35 mol) of (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluorophenylamino)-<br>
7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide are placed in 84<br>
litres of ethanol and heated to 70°C and combined with a solution of 2.94 kg (25.31<br>
mol) of maleic acid in 36 litres of ethanol. After crystallisation has set in, first the<br>
mixture is cooled to 20 °C and stirred for 2 hours, then for 3 hours at 0 °C. The<br>
precipitate is suction filtered, washed with 19 litres of ethanol and dried in vacuo at<br>
40°C.<br>
Yield: 8.11 kg (91.5%)<br>
Melting point: 178°C<br>
1H-NMR (CD3OD): 5 = 2.47 + 2.27 (m+m, 2H), 2.96 (s, 6H), 4.03 (m, 2H), 4.07 + 3.92<br>
(m+m, 2H), 4.18 + 4.03 (m+m, 2H), 5.32 (m, 1H), 6.26 (s, 4H), 6.80 (m, 1H), 6.99 (m,<br>
1H), 7.27(8, 1H), 7.30 (t, 1H), 7.66 (m, 1H), 7.96 (dd, 1H), 8.62 (s, 1H), 9.07 (s, 1H)<br>
ppm<br><br><br><br><br><br><br>
We claim:<br>
1.	Process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1 -oxo-2-buten-1 -yl]amino}-7-((S)- tetrahydrofuran-3-yloxy) -quinazoline of formula (VII)<br>
(Formula Removed)<br><br><br>
comprising the following synthesis steps:<br>
a)  Reacting       N4- (3-chloro-4-fluoro-phenyl) - 7- (tetrahydrofuran - 3 - yloxy) quinazoline-4,6-diamine of formula (V)<br>
(Formula Removed)<br>
in   suitable   solvents   after   corresponding   activation  with   di-(C1-4-alkyl)-phosphonoacetic acid and<br>
b) reacting the resulting di-(Ci-4-alkyl)-{[4- (3 -chloro - 4- fluoro-phenylamino) -7- ((S) - tetrahydrofuran - 3-yloxy)-quinazolin-6-ylcarbamoyl]-methyl}-phosphonate of formula (VI)<br>
(Formula Removed)<br><br><br>
 (VI) wherein    R1  denotes   C1-4-alkyl   group, with the aldehyde of formula<br>
(Formula Removed)<br>
or a corresponding aldehyde equivalent such as a hydrate or acetal, using suitable organic or inorganic bases to get the compound of formula VII.<br>
2.	Process      for      preparing      4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-<br>
dimethyl-amino)-l-oxo-2-buten-l-yl]ainino}-7-((S)-tetrahydrofuran-3-yloxy)-<br>
quinazoline as claimed in claim 1, comprising the following synthesis steps:<br>
a)	Reacting N4 - (3-chloro-4-fluoro-phenyl) - 7- (tetrahydrofuran- 3 - yloxy) quinazoline-4,6-diamine in suitable solvents after corresponding activation with di-(C1-4-alkyl)-phosphonoacetic acid and<br>
b)	reacting the resulting dialkylester {[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy) -quinazolin -6-ylcarbamoyl]-methyl}-phosphonate with the aldehyde prepared in situ from the corresponding (dimethylamino)-acetaldehyde-dialkylacetal using suitable organic or inorganic bases.<br>
3.	Process as claimed in claim 2, wherein as in step a) diethylphosphonoacetic<br>
acid is used as reagent.<br><br>
4.	Process as claimed in claim 1 or 2, wherein in step b) base is selected from DBU (1, 5-diaza-bicyclo[4.3.0]non-5-ene), sodium hydroxide or potassium hydroxide.<br>
5.	Process as claimed in claim 4, wherein in step b) base is potassium hydroxide.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUFic3RyYWN0KDI0LTAzLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Abstract(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUFic3RyYWN0LSgxMS0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Abstract-(11-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUFic3RyYWN0LSgyMC0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Abstract-(20-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUFic3RyYWN0LSgzMS0xMC0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Abstract-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNsYWltcygyNC0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Claims(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNsYWltcy0oMTEtMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Claims-(11-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNsYWltcy0oMjAtMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Claims-(20-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNsYWltcy0oMzEtMTAtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Claims-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWNvbXBsZXRlIHNwZWNpZmljYXRpb24gKGdyYW50ZWQpLnBkZg==" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-complete specification (granted).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMTItMTAtMjAxMSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Correspondence Others-(12-10-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDktMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Correspondence-Others-(09-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTEtMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Correspondence-Others-(11-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTItMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Correspondence-Others-(12-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTMtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Correspondence-Others-(13-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMzEtMTAtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Correspondence-Others-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWNvcnJlc3BvbmRlbmNlLW90aGVycy0xLnBkZg==" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-correspondence-others-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWRlc2NyaXB0aW9uIChjb21wbGV0ZSktKDI0LTAzLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-description (complete)-(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LURlc2NyaXB0aW9uIChDb21wbGV0ZSktKDMxLTEwLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Description (Complete)-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LURyYXdpbmdzLSgzMS0xMC0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Drawings-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMSgyNC0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-1(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMS0oMjAtMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-1-(20-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMS0oMzEtMTAtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-1-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMigyNC0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-2(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMi0oMjAtMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-2-(20-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMy0oMDktMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-3-(09-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUZvcm0tMy0oMTMtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Form-3-(13-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUdQQS0oMTItMTAtMjAxMSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-GPA-(12-10-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LUdQQS0oMzEtMTAtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-GPA-(31-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LXBjdC0xMDUucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-pct-105.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LXBjdC0zMDEucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-pct-301.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LXBjdC0zMDQucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-pct-304.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1kZWxucC0yMDA2LXBjdC0zMDgucGRm" target="_blank" style="word-wrap:break-word;">2029-delnp-2006-pct-308.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjAyOS1ERUxOUC0yMDA2LVBldGl0aW9uLTEzNy0oMTItMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">2029-DELNP-2006-Petition-137-(12-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QuanBn" target="_blank" style="word-wrap:break-word;">abstract.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="233061-an-electric-switch.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="233063-process-for-the-preparation-of-1-1-3-3-tetraalkylisoindoline-starting-from-n-benzylphthalimide.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>233062</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2029/DELNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>26-Mar-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>13-Apr-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>BOEHRINGER INGELHEIM INTERNATIONAL GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>Binger Strasse 173, 55216 Ingelheim, Germany</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>WERNER RALL</td>
											<td>Beethovenstrasse. 33, 88441 Mittelbiberach, Germany</td>
										</tr>
										<tr>
											<td>2</td>
											<td>RAINER SOYKA</td>
											<td>Geschwister-Scholl-Strasse. 43, 88400 Biberach, Germany</td>
										</tr>
										<tr>
											<td>3</td>
											<td>CHRISTIAN KULINNA</td>
											<td>Friedhofstrasse., 9, 88448 attenweiler, Germany</td>
										</tr>
										<tr>
											<td>4</td>
											<td>JUERGEN SCHNAUBELT</td>
											<td>Consulentengasse 16, 88400 Biberach, Germany</td>
										</tr>
										<tr>
											<td>5</td>
											<td>PETER SIEGER</td>
											<td>Klingenacker 7, 88441 Mittelbiberach, Germany</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 405/12</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2004/011378</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-10-12</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>103 49 113.9</td>
									<td>2003-10-17</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/233062-4-3-chloro-4-fluorophenyl-amino-6-4-n-n-dimethylamino-1-oxo-2-buten-1-yl-amino-7-s-tetrahydrofuran-3-yloxy-quinazoline by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:30:06 GMT -->
</html>
